Show simple item record

dc.contributor.authorMarsh, P J
dc.contributor.authorJames, Roger D
dc.contributor.authorSchofield, Philip F
dc.date.accessioned2010-04-21T10:40:50Z
dc.date.available2010-04-21T10:40:50Z
dc.date.issued1994-12
dc.identifier.citationAdjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial. 1994, 37 (12):1205-14 Dis. Colon Rectumen
dc.identifier.issn0012-3706
dc.identifier.pmid7995145
dc.identifier.doi10.1007/BF02257783
dc.identifier.urihttp://hdl.handle.net/10541/96991
dc.description.abstractPURPOSE: A prospective, randomized clinical trial was conducted by the Northwest Rectal Cancer Group to study the effects of preoperative radiotherapy given one week before surgery in locally advanced (tethered or fixed) rectal carcinoma. METHODS: A total of 284 patients were entered into the trial between 1982 and 1986; 141 were allocated to receive surgical treatment alone, and 143 were allocated to receive preoperative radiotherapy. A 10 x 10 x 10 cm volume in the posterior pelvis, centered on the tumor, was irradiated at a dose of 20 Gy, divided into four daily fractions of 5 Gy each. RESULTS: No differences were observed in any of the clinicopathologic variables in the two arms of the trial; there were no striking down-staging effects in the irradiated tumors. After a minimum follow-up period of 96 months, the overall and cancer-related mortality rates were similar in both arms of the study (P = 0.21 and P = 0.09, respectively). There was a highly significant reduction in local recurrences in the irradiated group (12.8 percent x-ray therapy vs. 36.5 percent surgery; P = 0.0001). The majority of local recurrences after preoperative radiotherapy occurred inside the radiotherapy field (10 cases; 7 percent), with only six cases (5 percent) outside the field. No significant difference was observed in the rates of distant metastasis between the two treatment groups (P = 0.73). CONCLUSIONS: Although there is no statistically significant survival benefit in the whole series, there is a survival benefit for the subset of patients considered by the surgeon to have undergone a curative operation. We recommend that this form of adjuvant therapy should be offered to all patients with locally advanced rectal cancer who are to undergo radical surgery.
dc.language.isoenen
dc.subjectCancer Metastasisen
dc.subjectCancer Recurrenceen
dc.subjectRectal Canceren
dc.subject.meshAged
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshPreoperative Care
dc.subject.meshProspective Studies
dc.subject.meshRadiotherapy Dosage
dc.subject.meshRadiotherapy, Adjuvant
dc.subject.meshRectal Neoplasms
dc.subject.meshSurvival Rate
dc.titleAdjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Christie Hospital National Health Service Trust, Withington, Manchester, United Kingdom.en
dc.identifier.journalDiseases of the Colon and Rectumen
html.description.abstractPURPOSE: A prospective, randomized clinical trial was conducted by the Northwest Rectal Cancer Group to study the effects of preoperative radiotherapy given one week before surgery in locally advanced (tethered or fixed) rectal carcinoma. METHODS: A total of 284 patients were entered into the trial between 1982 and 1986; 141 were allocated to receive surgical treatment alone, and 143 were allocated to receive preoperative radiotherapy. A 10 x 10 x 10 cm volume in the posterior pelvis, centered on the tumor, was irradiated at a dose of 20 Gy, divided into four daily fractions of 5 Gy each. RESULTS: No differences were observed in any of the clinicopathologic variables in the two arms of the trial; there were no striking down-staging effects in the irradiated tumors. After a minimum follow-up period of 96 months, the overall and cancer-related mortality rates were similar in both arms of the study (P = 0.21 and P = 0.09, respectively). There was a highly significant reduction in local recurrences in the irradiated group (12.8 percent x-ray therapy vs. 36.5 percent surgery; P = 0.0001). The majority of local recurrences after preoperative radiotherapy occurred inside the radiotherapy field (10 cases; 7 percent), with only six cases (5 percent) outside the field. No significant difference was observed in the rates of distant metastasis between the two treatment groups (P = 0.73). CONCLUSIONS: Although there is no statistically significant survival benefit in the whole series, there is a survival benefit for the subset of patients considered by the surgeon to have undergone a curative operation. We recommend that this form of adjuvant therapy should be offered to all patients with locally advanced rectal cancer who are to undergo radical surgery.


This item appears in the following Collection(s)

Show simple item record